Go Pro

Caxton Associates LLP Has $3.65 Million Stock Holdings in Azenta, Inc. $AZTA

Azenta logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Caxton Associates LLP increased its Azenta stake by 152.5% in the first quarter, buying 104,497 additional shares and bringing its total to 173,000 shares worth about $3.65 million.
  • Azenta reported mixed quarterly results, posting EPS of -$0.04 versus the expected $0.12 and revenue of $144.79 million, which also came in below estimates. Revenue was still up 1.4% year over year.
  • The stock was up 4.2% to $28.30, while analysts currently have a Hold consensus rating with an average price target of $40.40.
  • MarketBeat previews top five stocks to own in August.

Caxton Associates LLP lifted its stake in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 152.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 173,000 shares of the company's stock after purchasing an additional 104,497 shares during the quarter. Caxton Associates LLP owned 0.38% of Azenta worth $3,655,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Assenagon Asset Management S.A. boosted its stake in shares of Azenta by 249.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 96,602 shares of the company's stock worth $3,213,000 after buying an additional 68,955 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Azenta during the fourth quarter valued at approximately $36,803,000. Allspring Global Investments Holdings LLC lifted its holdings in Azenta by 7.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,388,047 shares of the company's stock valued at $46,347,000 after acquiring an additional 99,897 shares during the period. JPMorgan Chase & Co. lifted its holdings in Azenta by 7.6% in the third quarter. JPMorgan Chase & Co. now owns 473,315 shares of the company's stock valued at $13,594,000 after acquiring an additional 33,393 shares during the period. Finally, Stephens Investment Management Group LLC boosted its position in Azenta by 11.0% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,072,039 shares of the company's stock worth $35,656,000 after purchasing an additional 106,177 shares in the last quarter. Institutional investors and hedge funds own 99.08% of the company's stock.

Azenta Stock Up 4.2%

Shares of NASDAQ AZTA opened at $28.30 on Friday. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -7.15 and a beta of 1.37. The company's 50-day simple moving average is $23.46 and its 200-day simple moving average is $26.11. Azenta, Inc. has a 52-week low of $15.93 and a 52-week high of $41.73.

Azenta (NASDAQ:AZTA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.16). Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The company had revenue of $144.79 million during the quarter, compared to analysts' expectations of $148.47 million. During the same period in the prior year, the business posted $0.01 earnings per share. The company's quarterly revenue was up 1.4% compared to the same quarter last year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AZTA. Weiss Ratings raised shares of Azenta from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, July 15th. Needham & Company LLC lowered their price target on shares of Azenta from $44.00 to $33.00 and set a "buy" rating on the stock in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $40.40.

Read Our Latest Stock Report on AZTA

About Azenta

(Free Report)

Azenta, Inc NASDAQ: AZTA is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta's Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.

Featured Stories

Institutional Ownership by Quarter for Azenta (NASDAQ:AZTA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Azenta Right Now?

Before you consider Azenta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.

While Azenta currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines